There's still hunger for 'blockbuster' biotech deals
August 25, 2014 at 10:58 AM EDT
Roche's $8.3 billion deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.